Characteristics N =127
Female , N (%) 63 (50)
Median age; years (IQR) 41 (37-47)
Subject older than 50 years old, N (%) 23 (18)
Median BMI (kg/m), IQR 21.9 (19.6-24.6)
Median weight (BW) (kg), IQR 60(50-67)
Subject with BW> 60 kg, N (%) 55 (48)
Regimen prior to switching to ATV/r 200/100, N (%) ATV/r 300/100 mg
ATV 400 mg
IDV/r
LPV/r
SQV/r
EFV or NVP failure
61(48)
8 (6)
7 (6)
37 (29)
9 (7)
5 (4)
Reasons for switching to ATV/r 200/100 ATV plasma concentration >0.85 mg/L Asymptomatic hyperbilirubinemia Clinical Jaundice (symptomatic patients) Other (pill burden from other boosted PIs, low BW, or reduced cost) 44 (35)
20 (16)
10 (8)
53 (42)
Concomitant TDF TDF 300 mg alterative day TDF 300mg once daily 118 (93)
34 (29)
84 (71)
Median baseline CD4, cells/┬ÁL (IQR) 486 (368-696) ( range 14-1854)
Baseline HIV-RNA <50 copies/ml, N (%) 116 (91.3)
Median bilirubin, mg/dl (IQR) 1.3 (0.8-2.6)
Median eGFR, ml/min/1.73m2(IQR) 83 (74-99)
IQR : interquatile range, ATV/r : atzanavir/ritonavir, IDV/r: indinavir/ritonavir, SQV/r: saquinavir/ritonavir, LPV/r: lopinavir/ritonavir, EFV:efavirenz; NVP: nevirapine; TDF: tenofovir disproxil fumarate; eGFR: estimated glomerular filtration rate
Table 1: Baseline characteristics of 127 patients at time of initiating ATV/r 200/100 mg once daily.
Goto home»